




The Genomic Landscape Circa 2012

Eric Green, M.D., Ph.D.
Director, NHGRI



Current Topics in Genome Analysis 2012

Eric Green


*No Relevant Financial Relationships with
Commercial Interests*

Outline

- I. Historical Context for Genomics
- II. Major Achievements since the Human Genome Project
- III. The Human Genomics Landscape: 2012 and Beyond

>>> Goal: Place Future Speakers into a Broader Context <<<

Foundational Milestones in Genetics & Genomics




Mendel

1865




Miescher

1871



Avery




1944



**Watson
& Crick**


1953

April, 1953





The DNA Alphabet

G Guanine
A Adenine
T Thymine
C Cytosine



Human Genome: ~3 billion bases ('letters')

~21 Years Ago




October 1990
Human Genome Project Begins

~11 Years Ago



June 2000
Draft Human Genome Sequence Announced

~11 Years Ago



February 2001
Draft Human Genome Sequence Published

~9 Years Ago



April 2003
Human Genome Project Ends

guardian.co.uk




Adam Rutherford
guardian.co.uk, Thursday 21 April 2011 09.59 BST

[A larger](#) | [smaller](#)

The Human Genome Project was just the starting point

April 2011

“But the mistake that we often make is [saying that the Human Genome Project] was an end point. In fact, the Human Genome Project was a pregnancy... Ten years later, we now have a clue what we don’t yet know. The Human Genome Project may be finished, but understanding our genome is only just beginning.”




Genomic Medicine

Healthcare tailored to the individual based on genomic information



The top slide features a dark blue background with the title 'Genomic Medicine' in yellow. Below it, the subtitle 'Healthcare tailored to the individual based on genomic information' is written in white, italicized font. Three images are arranged horizontally: on the left, a hand in a blue glove holds a test tube containing a yellow liquid, with a background of green DNA sequence text; in the center, a doctor in a white coat and glasses looks at a tablet while a patient in a hospital gown looks on; on the right, a hand in a blue glove holds a test tube, with a background of white DNA sequence text.



The Path to Genomic Medicine




The bottom slide has a dark blue background with the title 'The Path to Genomic Medicine' in yellow. It shows a flow from left to right. On the left is the cover of 'nature the human genome' featuring a DNA double helix. This is followed by two white arrows, a large white question mark, and two more white arrows. On the right is a photo of a doctor and a patient. Below the first image is the text 'Human Genome Project' and below the second is 'Realization of Genomic Medicine'. A large red checkmark is at the bottom left, and a large red question mark is at the bottom right. The phrase 'Fulfilling the Promise' is written in yellow in the center.

Human Genome Project → → ? → → Realization of Genomic Medicine

"Fulfilling the Promise"



Coding Sequences (i.e., Genes)




The Genetic Code

~3,000 bp (0.0001%) of Human Genome Sequence


```
TGCCCGGAACTTTTCGGCTCTAAGGCTGATTTTGGATATCGAAAGGCACATTTTCCTCCCTTTTCAAAATGCACCTTGCAACGCTAACAG
GAACCCGACTAGGATCATCGGAAAAGGAGGAGGAGGAAGGCAGGCTCCGGGAAAGCTGGTGGCAGCGGGTCCCTGGGTCTGGCGACCCCTGA
CGGAAGGAGGGTCTAGGAAGCTCTCCGGGAGCCGGTTCCTCCGCGGGTGGCTTCTCTGCTCCTCCAGCGTTGCCAAGTGGACCTAAAGAGAGC
CCGCGACTGTCGCCACCTGCGGGATGGGCTGGTCTGGGCGGTAAGGACACGGAACCTGGAAGGAGCGCGCGGAGGGAGGGCTGGGAGTC
AGAATCGGAAAAGGAGCTGCGGGCGCCGAGGAGCGAAGGAGGAGGAGGAAAGGAGCGGGAGGGCTGCTGGCGGGTGCCTAGTGGGTGG
GAAAGCCGTAGAGCAAAATTTGGGCGGACAGGCGAGCTCGGCTTTTACCTGGGCGAGTGAAGCGGGGAAAGAGCAAAAGGAAGGGGTGG
TGTCCGAGTAGGGTGGTGGGGGAATTGGAAAGCAATGACATCACAGCAGGTCAGAGAAAAGGGTTGAGCGGCAGGCACCCAGAGTAGTAG
GTCTTTGGCATTAGGAGCTTGAGCCGACGCGCCCTAGCAGGGACCCAGCCCGCCGAGAGACCATGCAGAGGTCGCTCTGAAAAAGCCAGCGT
TGCTCCAAACTTTTTTCAGGTGAGAAGGTGGCCAAACGAGCTTCGGAAGACACGTCGCCACGAAAGAGGAGGGCGTGTGTATGGTGGGT
TGGGTAAAGGAATAGCAGTTTTTAAAAGATGCGCTATCATTCATTTGTTTGAAGAAAATGTGGCTATTTAGAAATAAAACAGAAAGCATT
AGAAGAGATGAAGAAATGAAGTGAAGCTGATGAATGAGAGCCACATCTACTTGAACGAAAAGTTAGAATCTCAAGACTCAAGTACGCTACT
ATGCACTTGTATTTTATTTTATTTTCAAGAAAATAAAATATCTGTTAATAAGTACCTAAGTATGGTTTATGGTTTTCCCTTCATGCTTGG
ACACTTGAATGCTCTTGGCACATACAGGTGCCATGCCATAGTATAGTAAAGTGCACAGAAAACATTTCTTACTGAATTCAGCCAAACAAAAT
TTGGGTAGGTAGAAAATATGCTTAAAGTATTTATTTGTTATGAGACTGGATATCTAGTATTTGACAGGTAATGATTTCTCAAAAATTTG
AAAGCAAAATTTGTTAAAATATTTTATTTGAAAAGTTACTTCAAGCTATAAATTTTAAAAGCCATAGGAATAGATACCGAAGTTATATCCAA
CTGACATTTAATAAATGTATTCATAGCCTAATGTGATGAGCCACAGAAGCTTGCAAACTTTAATGAGATTTTTTAAAATAGCATCTAAGTTCGG
AATCTTAGGCAAGTGTGTAGATGAGCACTTCATATTTGAAGTTCCTTTGGATATGCACTACTTTGTTCCCTGTATATATACTGGTGTGA
ATGAATGAATAGTACTGCTCTCTTGGGACATTAAGTACACATAAATACCCAAATGAATAAGCACTAGGAGTATCAAAAAGTCAAAATATGT
TATAAATAGCTCATATATGCTGTAAGGGGGAAGGAATTTAGCTTTCACATCTCTTATGTTTGTAGTCTCTGATGTCAGTAAATCTCTGGAAC
TCCGTTGCTAAGGAGAGCTTTGGCCCTTGAAGGAGAGCTCCCTCCCTGTTGATGAGAGAGAGGACTTTACTCTTTGGAATATCTTTTTCGT
TGATGTTATCCACTTTTGTACTCCACTATAAATCGGCTTATCTATGATCTGTTTCCCTAGTCCCTTATAAGTCAAAATGTTAATGGCAT
AAATATAGACTTTTTTATGACAGAGAACTTTAGGAACCTAAATGCCAACCAGCTCAAAAATGCAGTTTTTCAAGAATGAATATTTTCACTGGATA
GTCTAAATACATAAGAACTTTAAAATAGCTTACTATGATCTGTCAAAAGTGGTTTTTATATAAATTTCTTTTACAAATCACCTGACACATTT
AATATAGCTATAAATGCTATCAGCTGGTTTGAAGAAAATGTTATCAAAAGGCTGCTAAGTGTGTTAAGAGCATACCTATTTCTGTTCTCC
AAAATATTCATAAAGTCTTTAAGAAATAGGATGTTTTTAAAAGTTAAGTCTTACTATTTATAGGAACGCAATCACCTAAAATACCAATGA
TTCAAACTCCCTTGGCCCTCGGACTGCAATCTAAAAGTGAAAAAACATATTTTCGCAATTAAGTTAGGCAGTATGCTTAGTTTTCAA
GTGGTAGCTTTGGAGTCAGATTTTGAATCAGATCCTACATCTACTGTTTAGTAGCTCTGTGCTGAGGAGGTCCTTAACATCTCTGTG
TGCTATGACCTTTAAAATTTGGAGACTGTCATAGGGGTTAATCCCTTGAGAAAATGAATGTGAAAAGTTAGCCTAATGTTAATCTGCTATTT
ATGATTAACATAAATTTACATTCATCACAGTACATGCACCTGTTAATAAAGATGCTCAATTCATCTTTGAGTATAAATTTTGGACTCTCAAT
CTGGATATGCAATGAGTGGGCTGTATGAGAAATTAATTTATGAAAATTTGCTTTTACATGCGCTTACCAGATATACAGGAACACCTGACATG
TTCTATTTGATGTTTAAATGCCTTAGAATTTAATCTTCTGAATAGGATCCCTTCAAGTTTGGAGTCAAAAAGAGTAAAATTTATGGTAT
```

Foundational Milestones in Genetics & Genomics



Darwin

1859




Mendel

1865




Miescher

1871



Avery

1944




Watson
& Crick

1953

"It is not the strongest of the species that survives, nor the most intelligent that survives. It is the one that is the most adaptable to change."



(Attributed to Darwin)



Charles Darwin (1809-1882)

"For the last three and a half billion years, evolution has been taking notes."

—Eric Lander



Non-Coding Functional Sequences

Gene Regulation

Chromosome Packaging

Chromosome Segregation

Chromosome Replication

Non-Coding RNAs

The Human Genome... by the Numbers

~5% of Human Genome Sequence is Constrained Across Mammals (and Presumed Functional)

5% of 3B Bases = ~150M Bases
Do NOT Yet Know the Position of these ~150M Functional Bases
Lower Bound for the Amount that is Functional



~1.5% Encodes for Protein (Genes)

Corresponds to ~18-22K Genes
Many More than ~22K Different Proteins



~3.5% Functional But Non-Coding


Gene Regulatory Elements
Chromosomal Functional Elements
Undiscovered Functional Elements (NOT Yet in Textbooks!)

The Epigenomic Landscape




The ENCODE Portfolio






The screenshot shows the top portion of a PLoS Biology article. At the top, there are two genomic tracks. Below them is the PLoS logo and the text "OPEN ACCESS Freely available online". The article title is "A User's Guide to the Encyclopedia of DNA Elements (ENCODE)" by "The ENCODE Project Consortium". An abstract follows, describing the mission of the ENCODE project to understand human biology and improve health by integrating multiple technologies to discover and define functional elements in the human genome. The article is cited as "PLOS Biol (2011)".



The screenshot shows the website for the NIH Roadmap Epigenomics Mapping Consortium. The header includes "The NIH Common Fund" and "National Institutes of Health • U.S. Department of Health and Human Services". The main content area is titled "Epigenomics" and features an "OVERVIEW" section. The overview text states: "Epigenetics is an emerging frontier of science that involves the study of changes in the regulation of gene activity and expression that are not dependent on gene sequence. For purposes of this program, epigenetics refers to both heritable changes in gene activity and expression (in the progeny of cells or of individuals) and also stable, long-term alterations in the transcriptional potential of a cell that are not necessarily heritable. While epigenetics refers to the study of single genes or sets of genes, epigenomics refers to more global analyses of epigenetic changes across the entire genome." A "Related Information" sidebar lists links such as "What is Epigenomics?", "Scientific Illustration of How Epigenetic Mechanisms Can Affect Health", "PBS: A Tale of Two Mice (with Bradman)", and "Karate Black Belt Concentrates on". The website URL "nihroadmap.nih.gov/epigenomics" is displayed prominently below the screenshot. The article title "The NIH Roadmap Epigenomics Mapping Consortium" is shown in large text, followed by the list of consortium members: Bradley E Bernstein, John A Stamatoyannopoulos, Joseph F Costello, Bing Ren, Aleksandar Milosavljevic, Alexander Meissner, Manolis Kellis, Marco A Marra, Arthur L Beaudet, Joseph R Ecker, Peggy J Farnham, Martin Hirst, Eric S Lander, Tarjei S Mikkelsen & James A Thomson. The citation "Nature Biotechnology (2010)" is at the bottom.



TECHNOLOGY FEATURE
GENOMES IN THREE DIMENSIONS

A DNA sequence isn't enough; to understand the workings of the genome, we must study chromosome structure.

Nature (2011)

```
TGCCCGGAACTTTTCGGCTCTCTAAGGCTGATTTTGGATAT
ACGAAAGGCACATTTTCCCTCCCTTTTCAAATGCACCTTGC
AAACGTAACAGGAACCCGACTAGGATCATCGGAAAAGGAGG
AGGAGGAGAAAGCAGGCTCCGGGAAAGCTGTTGGCAGCGG
TCTCGGGTCTGGCGGACCTGACCGGAAGGAGGCTTAGGAA
GCTCTCCGGGAGCCGGTCTCCCGCCGGTGGCTTCTTCTGT
CCTCCAGCGTTGCCAATGGACCTAAAGAGAGGCCCGGACTG
TCGCCACCTTGGGGATGGGCTTGGCTGGCGGTAAGGAC
ACGGACCTGGAAAGGCGCCGCGAGGAGGGAGGCTGGGAG
TCAGAAATCGGAAAAGGAGGTGCGGGGCGCGAGGGAGCGAA
GGAGGAGAGGAGAAAGGAGCGGGAGGGGTGCTGGCGGGGTG
CGTAGTGGGTGGAAAGCCCGTAGAGCAAATTTGGGCGCG
ACCAGGCAGCACTCGGCTTTTAACTGGGCACTGAAGCGGG
GAAAGAGCAAAGGAGGGGTGGTGTGCGGAGTAGGGTGG
GTGGGGGAATTTGGAAGCAAATGACATCACAGCAGGTACAG
AAAAAGGTTGAGCGGCAGGCACCCAGAGTAGTGGTCTTTG
GCATTAGGAGCTTGAGCCAGAGCCCTAGCAGGGACCCCA
CGCCCCGAGAGCCATGCAGAGTCCCTCTGAAAAGGCCA
CGTGTCTCCAACTTTTTTTCAGGTGAGAGGTGGCCAA
CGAGCTTCGGAAGACAGTGCACCGAAAGAGGAGGGCGTG
TGTATGGTTGGTTTGGGTAAGGAATAAGCAGTTTTTAA
AAAGATCGCGTATCATTCTTTTGAAGAAAATGTGGGT
ATTGTAGAATAAACAGAAAGCATTAGAAGAGATGGAAGAA
TGAAGTGAAGCTGATTGAATAGAGGCCACATCTACTTGCAA
CTGAAAAGTTAGAATCTCAAGACTCAAGTACGCTACTATGCA
CTTGTATTATTTCATTTTCTAAGAACTAAAAACTTGT
AATAAGTACCTAAGTATGGTTTATGGTTTTCCCGCTTATG
CCTTGGACACTTGATTGTCTTGGCACATACAGGTGCCAT
GCCTGCATATAGTAACTGCTCAGAAAACATTTCTGACTGAA
TTCAGCCAACAAAATTTGGGGTAGGTAGAAAATATATGCT
TAAAGTATTATTGTATGAGACTGGATATATCTAGTATTG
TCACAGTAAATGATTTCTCAAATAATGAAAAGCAAATTTGT
GAAATATTATTGAAAAGTTACTTCACAGCTATAAAT
TTTAAAAGCCATAGGAATAGATCCGAAGTTATCCAACTG
ACATTTA
```



CLIFFS NOTES on U.S. \$4.95
The Human Genome Sequence

Cliffs
NOTES
YOUR KEY TO THE CLASSICS



The Genomics of Human Evolution



Genome 10K: A Proposal to Obtain Whole-Genome Sequence for 10 000 Vertebrate Species

GENOME 10K COMMUNITY OF SCIENTISTS*

J. Heredity (2009)



International HapMap Project

27 October 2009 | www.nature.com/nature | \$10 THE INTERNATIONAL WEEKLY JOURNAL OF SCIENCE

nature

Why do we sleep? **INSIDE**

OPTOELECTRONICS
Germanium boost for silicon chips

LAW OF THE JUNGLE
Don't ask a chimpanzee for help

MEN OF LETTERS
If Darwin and Einstein had e-mail...

THE HAPMAP PROJECT
Chapter and verse on human genetic variation

NATUREJOBS
Biodefence boom

A haplotype map of the human genome
The International HapMap Consortium*

Inherited genetic variation has a critical but as yet largely uncharacterized role in human disease. Here we report a public database of common variation in the human genome: more than one million single nucleotide polymorphisms (SNPs) for which accurate and complete genotypes have been obtained in 269 DNA samples from four populations, including ten 500-kilobase regions in which essentially all information about common DNA variation has been extracted. These data document the generality of recombination hotspots, a block-like structure of linkage disequilibrium and low haplotype diversity, leading to substantial correlations of SNPs with many of their neighbours. We show how the HapMap resource can guide the design and analysis of genetic association studies, shed light on structural variation and recombination, and identify loci that may have been subject to natural selection during human evolution.

2005

A second generation human haplotype map of over 3.1 million SNPs
The International HapMap Consortium*

We describe the Phase II HapMap, which characterizes over 3.1 million human single nucleotide polymorphisms (SNPs) genotyped in 270 individuals from four geographically diverse populations and includes 20–30% of common SNP variation in the populations surveyed. The map is extended to capture untyped common variation with an average maximum r^2 of between 0.9 and 0.96 depending on population. We demonstrate that the current generation of commercial genome-wide genotyping products captures common Phase II SNPs with an average maximum r^2 of up to 0.8 in African and up to 0.95 in non-African populations, and that potential gains in power in association studies can be obtained through imputation. These data also reveal novel aspects of the structure of linkage disequilibrium. We show that 10–20% of pairs of individuals within a population share at least one region of extended genetic identity arising from recent ancestry and that up to 1% of all common variants are untagable, primarily because they lie within recombination hotspots. We show that recombination rates vary systematically around genes, and between genes of different function. Finally, we demonstrate increased differentiation at non-synonymous SNPs, resulting from systematic differences in the strength or efficacy of natural selection between populations.

2007

Integrating common and rare genetic variation in diverse human populations
The International HapMap 3 Consortium*

Despite great progress in identifying genetic variants that influence human disease, most inherited risk remains unexplained. A more complete understanding requires genome-wide studies that fully examine less common alleles in populations with a wide range of ancestry. To inform the design and interpretation of such studies, we genotyped 1.6 million common single nucleotide polymorphisms (SNPs) in 1,184 reference individuals from 11 global populations, and sequenced ten 100-kilobase regions in 692 of these individuals. This integrated data set of common and rare alleles, called 'HapMap 3', includes both SNPs and copy number polymorphisms (CNPs). We characterized population-specific differences among low-frequency variants, measured the improvement in imputation accuracy afforded by the larger reference panel, especially in imputing SNPs with minor allele frequency of 1–5%, and demonstrated the feasibility of imputing newly discovered CNPs and SNP. This expanded public resource of genome variants in a global population supports deeper interrogation of genetic variation and its role in human disease, and serves as a step towards a high-resolution map of the landscape of human genetic variation.

2010

1000 Genomes
A Deep Catalog of Human Genetic Variation

nature
THE INTERNATIONAL WEEKLY JOURNAL OF SCIENCE

A THOUSAND GENOMES
Pilot studies prepare the way for population-scale gene sequencing **PAGE 1084**

BEYOND THE COURT CASE
Implications for the law, industry and ethics **PAGE 102**

OCEAN PRODUCTIVITY
Phosphate down the ages: key nutrient levels after "snowball" earth **PAGE 1054**



RETURN BOOTS
The recurring universe: Lee Smolin on Roger Penrose's grand idea **PAGE 1034**



ARTICLE
doi:10.1038/nature09534


A map of human genome variation from population-scale sequencing
The 1000 Genomes Project Consortium*

The 1000 Genomes Project aims to provide a deep characterization of human genome sequence variation as a foundation for investigating the relationship between genotype and phenotype. Here we present results of the pilot phase of the project, designed to develop and compare different strategies for genome-wide sequencing with high-throughput platforms. We undertook three projects: low-coverage whole-genome sequencing of 179 individuals from four populations; high-coverage sequencing of two mother-father-child trios; and exon-targeted sequencing of 697 individuals from seven populations. We describe the location, allele frequency and local haplotype structure of approximately 15 million single nucleotide polymorphisms, 1 million short insertions and deletions, and 20,000 structural variants, most of which were previously undescribed. We show that, because we have catalogued the vast majority of common variation, over 95% of the currently accessible variants found in any individual are present in this data set. On average, each person is found to carry approximately 250 to 1,000 low- or function variants in annotated genes and 50 to 100 variants previously implicated in inherited disorders. We demonstrate how these results can be used to inform association and functional studies. From the two trios, we directly estimate the rate of de novo germline base substitution mutations to be approximately 10^{-8} per base pair per generation. We explore the data with regard to signatures of natural selection, and identify a marked reduction of genetic variation in the neighbourhood of genes, due to selection at linked sites. These methods and public data will support the next phase of human genetic research.

Nature 2010










The First GWAS Success Story: Age-Related Macular Degeneration



Complement Factor H Polymorphism in Age-Related Macular Degeneration


Robert J. Klein,¹ Caroline Zeiss,^{2*} Emily Y. Chew,^{3*} Jen-Yue Tsai,^{4*} Richard S. Sackler,¹ Chad Haynes,¹ Alice K. Henning,⁵ John Paul SanGiovanni,³ Shrikant M. Mane,⁶ Susan T. Mayne,⁷ Michael B. Bracken,⁷ Frederick L. Ferris,³ Jurg Ott,¹ Colin Barnstable,² Josephine Hoh^{7†}

Science (2005)









A vision for the future of genomics research
A blueprint for the genomic era.

Francis S. Collins, Eric D. Green, Alan E. Guttmacher and Mark S. Guyer on behalf of the US National Human Genome Research Institute

in a few weeks by a single graduate student with access to DNA samples and associated phenotypes, an Internet connection to the public genome database, a thermal cycler and a DNA sequencing machine. With the


“...‘technological leaps’ that seem so far off as to be almost fictional but which, if they could be achieved, would revolutionize biomedical research and clinical practice.

[For example,]... the ability to sequence DNA at costs that are lower by four to five orders of magnitude than the current cost, allowing a human genome to be sequenced for \$1,000 or less.”

Nature, April 2003


Human Genome Sequence

~\$1,000,000,000




~\$1,000

“The \$1000 Genome”





Cost per Sequenced Human Genome



Human Genome Sequence

~\$1,000,000,000

~\$1,000

← **Current Cost**

“The \$1000 Genome”

Genome Sequencing as a ‘Commodity’

Sherlock Holmes
was an amateur.

SPECIAL PRICING \$4,998

Human Whole Genome Sequencing & Functional Interpretation (min. 10 genomes)

Investigating a genetic disease? We're the genome detectives to call. As experts in the functional interpretation of human genomes, we've built a state-of-the-art pipeline to richly annotate and thoroughly compare up to 300 whole genomes of exomes at once - to quickly track down the variants, genes, and pathways that govern disease. Starting with tissue samples, we deliver analyzed data, a shortlist of suspects, and powerful software to let you close the case in record time.

We can help you identify the variants, genes, and pathways that characterize a genetic disease. Visit www.knome.com/disease or call (857) 453-3895 to learn more.

Premier Scientific Partner

Roche NimbleGen (44Mb) Capture
 Illumina HiSeq 2000
 Capture All SNPs & Discover Rare Mutations


15,000 Exome/ Targeted Region Samples Sequenced by BGI to Date, and Counting


Human Exome Sequencing Starting at \$999

Target the most functionally relevant DNA sequences
 Capture both common and rare variants missed in traditional GWAS studies
 150 next-generation sequencers assure rapid turnaround
 1000 bioinformaticians generate high-quality, reliable data

America: (877) 590-0741
Europe: +45 5030807

www.tqjsequence.com






Ben didn't have an informatics bottleneck.

SPECIAL PRICING \$3,750 per genome Includes whole genome sequencing (30x), downstream informatics & interpretation tools

Introducing knomeBASE™, an informatics service that transforms raw sequence data from human genomes into a format optimized for desktop interpretation. knomeBASE annotates, compares, and distills sequence data—addressing the primary informatics challenges that typically bottleneck the process of interpreting whole genomes. Clients also receive a suite of software tools, scripts, and libraries that give geneticists unprecedented flexibility to query, visualize, and interpret multiple genomes.

Knome
The human genome interpretation company™

Downstream informatics & interpretation tools for geneticists: visit www.knome.com





~11 Months Ago

PERSPECTIVE

Charting a course for genomic medicine from base pairs to bedside

Eric D. Green¹, Mark S. Cooper² & National Human Genome Research Institute¹

There has been much progress in genomics in the ten years since a draft sequence of the human genome was published. Opportunities for understanding health and disease are now unprecedented, as advances in genomics are harnessed to obtain more functional knowledge about the structure and function of the human genome and about the genetic contribution to human health and disease. Here we articulate a 2011 vision for the future of genomics research and describe the path towards an era of genomic medicine.



Since the start of the Human Genome Project (HGP) in 2001 and the release of a reference human genome sequence, genomics has become a reality of clinical practice. The central concept of the HGP's flagship international project, a public release of the complete sequence of the HGP reference genome, has been the driving force behind the development of a wide range of new genomic technologies and the resulting explosion of genomic data. The resulting explosion of genomic data has led to a number of important discoveries, such as the identification of disease-causing genes, the discovery of new genes, the identification of new genetic variants, and the discovery of new genetic variants associated with disease. Other important discoveries include the identification of new genetic variants associated with disease, the discovery of new genetic variants associated with disease, and the discovery of new genetic variants associated with disease.



Understanding the biology of genomes is a complex task, and it is a complex task to understand the complexity of genome biology. Continued expansion of our knowledge about genome structure and function is needed to illuminate further the complexity (Fig. 2). The central theme of genomics will be to understand the complexity of genomes and to use this knowledge to improve human health and to advance our understanding of the biology of genomes.

Genomic studies of the genome and pathways associated with disease have been a major focus of genomics research, which has led to the discovery of new genetic variants associated with disease. This research has been a major focus of genomics research, which has led to the discovery of new genetic variants associated with disease. This research has been a major focus of genomics research, which has led to the discovery of new genetic variants associated with disease.


February 2011

NHGRI Published New Vision for Genomics





2011 NHGRI Strategic Plan for Genomics



BOX 2
Imperatives for genomic medicine

Opportunities for genomic medicine will come from simultaneously acquiring foundational knowledge of genome function, insights into disease biology and powerful genomic tools. The following imperatives will capitalize on these opportunities in the coming decade.

Making genomics-based diagnostics routine. Genomic technology development so far has been driven by the research market. In the next decade, technology advances could enable a clinician to acquire a complete genomic diagnostic panel (including genomic, epigenomic, transcriptomic and microbiomic analyses) as routinely as a blood chemistry panel.



Defining the genetic components of disease. All diseases involve a genetic component. Genome sequencing could be used to determine the genetic variation underlying the full spectrum of diseases, from rare Mendelian to common complex disorders, through the study of upwards of a million patients; efforts should begin now to organize the necessary sample collections.

Comprehensive characterization of cancer genomes. A comprehensive genomic view of all cancers^{4,7} will reveal molecular taxonomies and altered pathways for each cancer subtype. Such information should lead to more robust diagnostic and therapeutic strategies and a roadmap for developing new treatments^{4,7,8}.

Practical systems for clinical genomic informatics. Thousands of genomic variants associated with disease risk and treatment response are known, and many more will be discovered. New models for capturing and displaying these variants and their phenotypic consequences should be developed and incorporated into practical systems that make information available to patients and their healthcare providers, so that they can interpret and reinterpret the data as knowledge evolves.

The role of the human microbiome in health and disease. Many diseases are influenced by the microbial communities that inhabit our bodies (the microbiome)¹⁰. Recent initiatives^{10,11} (<http://www.human-microbiome.org>) are using new sequencing technologies to catalogue the resident microflora at distinct body sites, and studying correlations between specific diseases and the composition of the microbiome¹⁰. More extensive studies are needed to build on these first revelations and to investigate approaches for manipulating the microbiome as a new therapeutic approach.







Cell Leading Edge
Commentary

Cell (2011)

Genomics Reaches the Clinic: From Basic Discoveries to Clinical Impact

Teri A. Manolio¹ and Eric D. Green^{1,*}
¹National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
^{*}Correspondence: egreen@nhgri.nih.gov
DOI 10.1016/j.cell.2011.09.012

Today, more than ever, basic science research provides significant opportunities to advance our understanding about the genetic basis of human disease. Close interactions among laboratory, computational, and clinical research communities will be crucial to ensure that genomic discoveries advance medical science and, ultimately, improve human health.



The Future: Genome Sequencing



Cancer Genomics

ICGC Cancer Genome Projects

Committed projects to date: 36


Sort by: Project


Bladder Cancer United States	Blood Cancer United States	Bone Cancer United Kingdom
Brain Cancer United States	Breast Cancer European Union / United Kingdom	Breast Cancer France




Genomic Medicine: Clinical Microbiology

Now







Future




+



=





All of these work.

Just not for everyone.

Perlegen may be able to help you sort out which medicine helps which patient.

Working with you, we can comprehensively analyze the DNA from thousands of patients taking your drug. Out of the millions of genetic variations between patients, we may be able to help you identify the ones that are associated with strong efficacy, poor efficacy, or side effects.

Perlegen's exceptional coverage of the genome and experienced team of analysts could help you get clinically relevant answers, not just data, in a matter of months.


We partner with the top pharmaceutical companies around the world. We also license late-stage drugs. If you have a drug that can benefit from our approach, please contact us.


Patients are waiting.
genetics@perlegen.com
Mountain View, California • 650-625-4500
Tokyo, Japan • 51 (0)3 3444-6080
www.perlegen.com

Targeting today's drugs.
Discovering tomorrow's.™

PERLEGEN
SCIENCE

© 2009 Perlegen





Understanding the Structure of Genomes	Understanding the Biology of Genomes	Understanding the Biology of Disease	Advancing the Science of Medicine	Improving the Effectiveness of Healthcare
				
<p>A pessimist sees the difficulty in every opportunity. An optimist sees the opportunity in every difficulty.</p> <p><i>--Winston Churchill</i></p>				



genome.gov



THE BRIGHT FUTURE
OF HUMAN
GENOMICS